Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TScan Therapeutics, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing TCR-engineered T cell therapies. Its 8-K filings furnish operating results, corporate presentations, and pipeline disclosures tied to TSC-101, the ALLOHA heme program, CD45-targeted candidates, solid-tumor research, and autoimmunity target discovery.
The company’s filings also cover governance and capital-structure matters, including officer role changes, compensation and retention arrangements, costs associated with portfolio prioritization, and proxy proposals for director elections, auditor ratification, and authorized common stock. The records identify TCRX voting common stock as listed on the Nasdaq Global Market.
Lynx1 Capital Management LP and Weston Nichols filed Amendment No.2 to a Schedule 13G reporting beneficial ownership of 7,857,347 shares of TScan Therapeutics voting common stock, representing 15.0% of the class. The percentage is calculated using 52,314,039 shares outstanding as of May 7, 2025, and the shares are directly held by Lynx1 Master Fund LP.
The cover data shows 0 shares as sole voting or dispositive power and 7,857,347 shares as shared voting and dispositive power. The filing is a Schedule 13G with a certification that the securities were not acquired to change or influence control. The statement is signed by Weston Nichols on behalf of Lynx1 and individually, dated 08/14/2025.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,350,000 shares of TScan Therapeutics Voting Common Stock issuable upon exercise of warrants. These shares represent 2.52% of the company's Voting Common Stock based on an aggregate of 52,314,039 shares outstanding used for the calculation. The filing shows shared voting and dispositive power over the 1,350,000 warrant‑issued shares and no sole voting or dispositive power.
This position is reported as holdings through Adage affiliates and reflects potential future dilution if the warrants are exercised; the reported amount is not currently held as sole-owned shares.
TScan Therapeutics reported results for the quarter ended June 30, 2025, reflecting continued investment in its TCR-T therapy pipeline and collaborations. Revenue for the quarter was $3.1 million ( $5.2 million for the six months), driven by research activity under the Amgen collaboration that included a $30 million upfront payment. R&D and G&A increased to $32.6 million and $9.1 million for the quarter, respectively, resulting in a quarterly net loss of $37.0 million (six-month net loss $71.1 million), or $0.28 per share for the quarter.
The company held $169.4 million in cash and cash equivalents and $48.7 million in marketable securities as of June 30, 2025 (totaling ~$218.0 million excluding restricted cash), which management says supports operations into the first quarter of 2027. Long-term debt included a SVB term loan with $32.5 million principal outstanding and an effective interest rate of 8.46%. The filing also highlights regulatory progress with multiple Phase 1 INDs and continued R&D expenditures, alongside disclosed risks and expected ongoing losses.
TScan Therapeutics announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025. The Current Report states the press release is furnished as Exhibit 99.1 and that the information is furnished, not filed, so it is not subject to Section 18 liability or automatically incorporated by reference into other filings. The filing identifies the company as an emerging growth company and confirms its common stock trades under the symbol TCRX on the Nasdaq Global Market. The report is signed on the company’s behalf by Chief Executive Officer Gavin MacBeath.